Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries
David Brieger(The University of Sydney), Shaun G. Goodman(University of Toronto), Christopher B. Granger(Clinical Research Institute), Satoshi Yasuda(Tohoku University), John Gregson(London School of Hygiene & Tropical Medicine), Stuart Pocock(London School of Hygiene & Tropical Medicine), Karolina Andersson Sundell(AstraZeneca (Brazil)), Stefan Blankenberg(Universität Hamburg), Katarina Hedman(AstraZeneca (Brazil)), Dirk Westermann(University Medical Center Freiburg), Tabassome Simon(Sorbonne Université), Kirsten L. Rennie(University of London), Richard Grieve(MRC Clinical Trials Unit at UCL), José Carlos Nicolau(Hospital São Paulo), Ji Yan Chen(Guangdong General Hospital), Mauricio G. Cohen(Santa Ana College)
Cited by 14
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery
|New England Journal of Medicine|2010|7.2k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients
|New England Journal of Medicine|2011|6.4k
Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients
|New England Journal of Medicine|2019|4.8k